Business profile & competitive position
Becton, Dickinson and Company (BDX) is a Healthcare company in the Medical – Instruments & Supplies industry. It develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products used by hospitals, physicians, clinical laboratories, pharmaceutical companies and life-science researchers. As of September 30, 2025, BD operated through three worldwide segments: BD Medical, BD Life Sciences and BD Interventional. Its solutions cover medication management, patient safety, infection prevention, surgical and interventional procedures, drug delivery, anesthesiology, infectious-disease and cancer diagnostics, and cellular research.
The company’s competitive position looks more like durable breadth than exceptional profitability. Net margin is 4.5% and return on equity is 3.8%, both modest for a large-cap medical technology franchise. Those figures do not point to outsized pricing power; instead they suggest a business whose strength lies in scale, long-standing customer relationships and a wide product catalog with switching costs in clinical settings. A five-year, double-digit ROE would typically signal strong pricing power, but 3.8% ROE says capital efficiency is currently muted, possibly because of recent integration costs, segment restructuring or mix pressures.
Financial posture
BDX carries a $54.1 billion market capitalization and trades at a 59.8x trailing P/E ratio. Relative to a 4.5% net margin and 3.8% ROE, that is a steep valuation: the market is pricing in meaningful earnings expansion, margin recovery or value unlocked by the ongoing portfolio reshaping. The stock’s beta is just 0.28, indicating very low sensitivity to broader equity-market moves, consistent with the defensive demand characteristics of medical supplies and devices.
At the current snapshot, BD closed at $198.60 with a 50-day EMA of $186.03, so price sits roughly 6.8% above the near-term trend. The RSI of 65.0 is approaching but not yet in traditionally overbought territory. None of these figures say whether the stock is cheap or expensive on an absolute basis, but the combination of a high P/E, low beta and slim margins explains why each earnings report and strategic update can move the multiple more than the typical industrial stock.
Strategic priorities & outlook
BD’s most recent 10-K filing outlines several decisive operational moves. Effective October 1, 2025, BD reorganized into five separately-managed segments: Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. That resegmentation is the clearest near-term structural change; investors will want to watch how the company reports revenue and margin by those new divisions.
The company is also pursuing a Reverse Morris Trust combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close around the end of the first calendar quarter of 2026. BD expects to receive approximately $4 billion in cash and its shareholders are slated to own roughly 39.2% of the combined company after the transaction. That is a large liquidity event and a significant reshaping of BD’s remaining portfolio.
On the acquisition side, BD completed the $3.914 billion purchase of Edwards Lifesciences’ Critical Care product group in September 2024, integrating it as BD Advanced Patient Monitoring within BD Medical. Balance-sheet flexibility is also influenced by divestitures: BD spun off its Diabetes Care business as Embecta Corp. in April 2022 and sold the Interventional segment’s Surgical Instrumentation platform in August 2023, booking a pre-tax gain of about $268 million on the latter sale.
Operationally, BD manufactures in 18 countries outside the United States across EMEA, Greater Asia, Latin America and Canada. It explicitly notes that foreign economic conditions and exchange-rate fluctuations make overseas profitability more volatile than domestic profitability.
Macro & geopolitical exposure
As a Medical – Instruments & Supplies company, BD sits at the intersection of healthcare regulation, reimbursement policy and global manufacturing logistics. The sector is exposed to U.S. FDA device-clearance timelines, hospital purchasing decisions tied to Medicare and private-payer reimbursement, and quality-system inspections. Trade policy matters because many devices and components cross borders; tariffs or customs delays could affect production cost and supply cadence.
Currency risk is also material. BD’s 10-K states that non-U.S. revenues create profitability swings that are larger than those of domestic revenues, and it cites exchange-rate fluctuations as a specific headwind. Raw-material exposure includes resins, specialty metals and electronic components used in disposable and capital equipment. Inflation in logistics and labor can pressure the already modest 4.5% net margin. Geopolitically, operations across EMEA, Greater Asia and Latin America create diverse revenue streams but also require compliance with multiple regulatory regimes.
Recent developments
The most company-specific recent headline came on November 2, 2026, when Zacks reported that BD launched its Liverty TIPS stent graft to expand U.S. treatment options. The TIPS (transjugular intrahepatic portosystemic shunt) market is a narrow but specialized corner of BD’s Interventional portfolio; launches like this can help replace revenue lost after divesting lower-growth platforms.
On October 31, 2026, Seeking Alpha included Becton Dickinson among 14 dividend-growth companies expected to announce annual dividend increases during the first half of November. That places BD in a group of cash-flow-oriented compounders, even though its current earnings multiple reflects growth expectations as well as income.
On October 29, 2026, Zacks published a preview titled “Becton Dickinson (BDX) Earnings Expected to Grow: Should You Buy?” and an American Century Equity Income Fund Q3 2026 portfolio activity note also dated October 29 appeared on Seeking Alpha. These items frame the immediate catalyst: the November 5, 2026 earnings release before the market open, where the consensus EPS estimate stands at $4.07.
Earnings behavior & post-earnings drift
BD has beaten the official consensus in all of the last eight reported quarters, for a 100% beat rate. The average earnings surprise over those eight quarters is 8.2%. Looking at the five trading days following each report, the average price move has been +3.66%, classified as an upward post-earnings drift. That is a meaningful tendency in the data, even if the one-day reaction sometimes goes the other way.
The last four quarter reports show a mixed pattern between first-day and five-day performance:
- August 6, 2026: actual EPS of $3.23 versus an estimate of $3.14, a 2.9% surprise. The stock fell 0.12% the next day but drifted up 2.77% over the following five sessions.
- May 7, 2026: actual EPS of $2.90 versus an estimate of $2.78, a 4.3% surprise. The stock dropped 2.5% the next day and extended losses to -5.74% over the next five sessions.
- February 9, 2026: actual EPS of $2.91 versus an estimate of $2.21, a 31.7% surprise. The stock rallied 5.3% the next day and 8.8% over the next five sessions.
- November 6, 2025: actual EPS of $3.96 versus an estimate of $3.92, a 1.0% surprise. The stock moved up 0.25% the next day and climbed 8.82% over the subsequent five sessions.
Heading into the November 5, 2026 report, the unofficial consensus is $4.07 and the stock is priced for a continuation of the beat streak. The recent August quarter showed that even a solid beat can produce a flat one-day response if expectations are already priced in, so traders and investors should distinguish between the headline EPS beat and how the market chooses to value the guidance, segment margins and any update on the Waters transaction.
Frequently Asked Questions
What does Becton Dickinson actually do?
BD is a global medical technology company that develops, manufactures and sells medical supplies, devices, laboratory equipment and diagnostic products for healthcare institutions, physicians, clinical laboratories, pharmaceutical companies and researchers. As of September 30, 2025, it operated through BD Medical, BD Life Sciences and BD Interventional.
What are BD’s main strategic priorities right now?
BD reorganized into five segments effective October 1, 2025, and is pursuing a Reverse Morris Trust combination of its Biosciences and Diagnostic Solutions business with Waters Corporation, expected to close around the end of Q1 2026. It expects roughly $4 billion in cash and a 39.2% stake in the combined company for its shareholders. It also integrated the $3.914 billion Edwards Lifesciences Critical Care acquisition as BD Advanced Patient Monitoring.
How has BD performed around earnings?
Over the last eight reported quarters, BD has beaten the consensus every time, with an average earnings surprise of 8.2%. The average five-day post-earnings price move has been +3.66%, indicating an upward drift, even though individual quarters such as May 2026 posted a short-term decline.
For a deeper dive into how sell-side and quantitative models are interpreting BD’s reorganization, Waters transaction and upcoming earnings report, review the full institutional verdict rather than relying on any single snapshot.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-08-06 | $3.23 | $3.14 | +2.9% | -0.12% | +2.77% |
| 2026-05-07 | $2.9 | $2.78 | +4.3% | -2.5% | -5.74% |
| 2026-02-09 | $2.91 | $2.21 | +31.7% | +5.3% | +8.8% |
| 2025-11-06 | $3.96 | $3.92 | +1% | +0.25% | +8.82% |
| 2025-08-07 | $3.68 | $3.4 | +8.2% | - | - |
| 2025-05-01 | $3.35 | $3.28 | +2.1% | - | - |
Previous BDX editions
Get the institutional verdict on BDX
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the BDX verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.